News | January 21, 2013

Varian Receives Regulatory Clearance in India for Use of High Intensity Mode on TrueBeam Medical Linear Accelerators

January 21, 2013 — Varian Medical Systems received regulatory clearance from the Indian Atomic Energy Regulatory Board for the use of its TrueBeam high-intensity mode for advanced radiosurgical treatments.

Dr. Vivek Bansal, director of radiation oncology at HCG Cancer Hospital in Ahmedabad — the first hospital in India to commence treating patients using the TrueBeam high-intensity mode — said, "We have used this modality for prostate, head and neck, and lung cancer patients, enabling quicker dose delivery and therefore shorter treatments. Higher dose rates appear to offer considerable benefits in organ motion management — for example, larger dose fractions have been delivered in a single breath-hold at our center."

"We feel high-intensity modes may become necessary for most stereotactic ablative body radiotherapy and stereotactic radiosurgery treatments in the future," said Bansal. "Our experience is showing that high-intensity mode treatments offer particular advantages when treating the smaller field sizes normally seen in such treatments."

Varian's TrueBeam was designed to treat tumors with unprecedented speed and accuracy. It features a multitude of technical innovations that dynamically synchronize imaging, patient positioning, motion management and treatment delivery. With its high-intensity mode, TrueBeam machines can deliver very high doses quickly and precisely, more than twice as fast as earlier generations of technology. The TrueBeam STx is a high-end model optimized for radiosurgical applications, where very large doses are delivered in a single treatment or only a few sessions.

"The high dose rates that only Varian can offer on its medical linear accelerators are vital for the sort of stereotactic ablative radiotherapy treatments that are used increasingly for primary liver, liver metastasis and lung cancer treatments," said Rolf Staehelin, international head of marketing operations for Varian's Oncology Systems group. "Regulatory approval means cancer patients in India can now benefit from such advanced treatments."

"With the largest installed base of linear accelerators in India and market-leading position in new systems, Varian continues to equip the country's cancer hospitals with technologies that make advanced radiotherapy techniques fast and easy to deliver," added Ashok Kakkar, managing director of Varian India. "We have also established a dedicated education center in Mumbai because helping to train the nation's radiotherapists and physicists in the safe and effective use of Varian's products is crucial for the future care of India's growing cancer population."

For more information: www.varian.com

Related Content

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline).

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline). See more figures from this study.

Feature | Radiation Therapy | September 28, 2021
September 28, 2021 — New research from Washington University School of Medicine in St.
The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 billion in 2021 at a compound annual growth rate (CAGR) of 7.5%

Varian's Ethos artificial intelligence radiotherapy device.

News | Radiation Oncology | September 28, 2021
September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.

Getty Images

News | Prostate Cancer | September 24, 2021
September 24, 2021 — Scientists have identified two subtypes of metastatic...
The "Global Surface Guided Radiation Therapy (SGRT) Devices Market, By Device Type (Portable v/s Fixed), By Application (Breast Cancer, Head & Neck Cancer, Abdominal & Pelvic Cancer, Dermatology, Others), By End User, By Region, Competition Forecast & Opportunities, 2026" report

Image courtesy of Varian

News | Radiation Therapy | September 24, 2021
September 24, 2021 — The ...
The National Cancer Institute announced that Virginia Commonwealth University Massey Cancer Center, Medical University of South Carolina Hollings Cancer Center and City of Hope Comprehensive Cancer Center secured a highly competitive Specialized Program of Research Excellence (SPORE) grant that aims to address lung cancer racial disparities through precision medicine, targeted smoking cessation programs and community outreach.

VCU Massey Cancer Center director and SPORE principal investigator Dr. Robert Winn explains how this grant will help combat racial inequities in lung cancer. Image courtesy of VCU Massey Cancer Center

News | Lung Imaging | September 23, 2021
September 23, 2021 — The National Cancer Institute announced tha
The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...